Insmed Shares Surge on Positive Phase 3b ENCORE Trial Results for ARIKAYCE, Signaling Expanded Role in MAC Lung Disease Treatment
**” Insmed Incorporated’s shares climbed significantly following the release of positive topline data from the Phase 3b ENCORE study of ARIKAYCE (amikacin liposome inhalation suspension). The trial met its primary endpoint with statistically significant improvements in respiratory symptoms and achieved all key secondary endpoints related to culture conversion in newly diagnosed, antibiotic-naive patients with Mycobacterium … Read more